Cardiovascular disease in recent onset diabetes mellitus.

[1]  S. Yamagishi,et al.  Combination Therapy with Nateglinide and Telmisartan Ameliorates Insulin Resistance in Zucker Fatty Rats by Suppressing Advanced Glycation End Product Receptor Axis , 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[2]  A. Ceriello,et al.  The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. , 2010, Diabetes research and clinical practice.

[3]  S. Yamagishi,et al.  An α-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes , 2010, Clinical and Experimental Medicine.

[4]  S. Yamagishi.  Advanced Glycation End Products and Receptor–Oxidative Stress System in Diabetic Vascular Complications , 2009, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[5]  A. Ceriello.  Hypothesis: the "metabolic memory", the new challenge of diabetes. , 2009, Diabetes research and clinical practice.

[6]  R. Vasan,et al.  Triglycerides as vascular risk factors: new epidemiologic insights , 2009, Current opinion in cardiology.

[7]  A. Ceriello.  The metabolic memory , 2009 .

[8]  S. Yamagishi,et al.  Clinical Utility of Acarbose, an α-Glucosidase Inhibitor in Cardiometabolic Disorders , 2009 .

[9]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[10]  S. Yamagishi,et al.  Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications , 2008, Expert opinion on investigational drugs.

[11]  A. Saiki,et al.  Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. , 2008, Journal of atherosclerosis and thrombosis.

[12]  T. Yoshikawa,et al.  The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[13]  U. Smith,et al.  Inflamed Adipose Tissue: A Culprit Underlying the Metabolic Syndrome and Atherosclerosis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[14]  A. Hamsten,et al.  Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. , 2007, Atherosclerosis.

[15]  S. Yamagishi,et al.  Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. , 2007, Current molecular medicine.

[16]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[17]  N. Katsilambros,et al.  High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria Published, JLR Papers in Press, October 3, 2006. , 2007, Journal of Lipid Research.

[18]  H. Daida,et al.  Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. , 2006, Biochemical and biophysical research communications.

[19]  Jean-Paul Cristol,et al.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.

[20]  N. Takasu,et al.  Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. , 2006, The Journal of clinical endocrinology and metabolism.

[21]  A. Ceriello,et al.  Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. , 2005, Atherosclerosis.

[22]  T. Imaizumi,et al.  Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. , 2005, Current pharmaceutical design.

[23]  R. Marfella,et al.  Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus , 2004, Circulation.

[24]  A. Cavarape,et al.  The post‐prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[25]  Antonio Ceriello,et al.  Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. , 2003, Diabetes.

[26]  W. Hsueh,et al.  Role of endothelial dysfunction in insulin resistance. , 2003, The American journal of cardiology.

[27]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[28]  Claude Colette,et al.  Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). , 2003, Diabetes care.

[29]  A. Ceriello,et al.  Evidence for an Independent and Cumulative Effect of Postprandial Hypertriglyceridemia and Hyperglycemia on Endothelial Dysfunction and Oxidative Stress Generation: Effects of Short- and Long-Term Simvastatin Treatment , 2002, Circulation.

[30]  A. Ceriello,et al.  Role of hyperglycemia in nitrotyrosine postprandial generation. , 2002, Diabetes care.

[31]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[32]  B. Szwergold,et al.  alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. , 2001, Diabetes care.

[33]  H. Iso,et al.  Serum triglycerides and risk of coronary heart disease among Japanese men and women. , 2001, American journal of epidemiology.

[34]  S. Jackson,et al.  The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. , 2001, Atherosclerosis.

[35]  Y. Iwamoto,et al.  Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. , 2000, Diabetes care.

[36]  S. Kiechl,et al.  Impaired glucose tolerance, Type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study , 2000, Diabetologia.

[37]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[38]  A Sekikawa,et al.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. , 1999, Diabetes care.

[39]  M. Hanefeld,et al.  Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. , 1999, Atherosclerosis.

[40]  M. Laakso,et al.  Hyperglycemia and cardiovascular disease in type 2 diabetes. , 1999, Diabetes.

[41]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[42]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[43]  M. Hanefeld,et al.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.

[44]  M. Pirisi,et al.  Hyperglycemia-Induced Thrombin Formation in Diabetes: The Possible Role of Oxidative Stress , 1995, Diabetes.

[45]  M. Laakso,et al.  NIDDM and Its Metabolic Control Predict Coronary Heart Disease in Elderly Subjects , 1994, Diabetes.

[46]  M. Laakso,et al.  Non‐Insulin‐Dependent Diabetes and Its Metabolic Control Are Important Predictors of Stroke in Elderly Subjects , 1994, Stroke.

[47]  L. Niskanen,et al.  Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (non-insulin-dependent) diabetic and non-diabetic subjects , 1993, Diabetologia.

[48]  M. Shipley,et al.  CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall Study , 1980, The Lancet.

[49]  K. Pyörälä.  Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in Finland , 1979, Diabetes Care.

[50]  I. Pless,et al.  West Indian one-year-olds. A comparative analysis of health and service utilisation. , 1967, Lancet.

[51]  S. Yamagishi,et al.  Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. , 2009, Current drug metabolism.

[52]  S. Yamagishi,et al.  Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. , 2008, Current medicinal chemistry.

[53]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[54]  K. Pyörälà,et al.  Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. , 1979, Diabetes care.